Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as I...
Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy: e0123866
About this item
Full title
Author / Creator
Journal title
Language
English
Formats
More information
Scope and Contents
Contents
Objective Subcutaneous (SC) application of bortezomib has been recently introduced as a new application route in multiple myeloma (MM) patients. We performed an analysis to compare the outcomes of bortezomib-based therapy in multiple myeloma (MM) patients treated using either intravenous (IV) or subcutaneous (SC) route of administration. Patients a...
Alternative Titles
Full title
Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy: e0123866
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1680434658
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1680434658
Other Identifiers
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0123866
